VYNE Therapeutics (VYNE) Treasury Shares (2016 - 2025)
VYNE Therapeutics (VYNE) posted Treasury Shares of $450916.0 for Q4 2025, down 39.94% on a QoQ basis from $750715.0 in Q4 2024, and down 39.94% year-over-year from $750715.0 in Q4 2024.
VYNE Therapeutics (VYNE) Treasury Shares (2016 - 2025) Analysis & Trends
VYNE Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $450916.0 for Q4 2025.
- Quarterly Treasury Shares fell 39.94% year-over-year to $450916.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $450916.0 (down 39.94% YoY) and the FY2025 annual result came in at $450916.0, down 39.94% from the prior year.
- Treasury Shares was $450916.0 for Q4 2025 at VYNE Therapeutics, down from $750715.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $750715.0 in Q4 2024 and bottomed at $3000.0 in Q4 2022.
- A 4-year average of $416402.5 and a median of $455947.5 in 2023 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares jumped 15265.97% — and 2025, when it sank 39.94%.
- VYNE Therapeutics' Treasury Shares stood at $3000.0 in 2022, then soared by 15265.97% to $460979.0 in 2023, then soared by 62.85% to $750715.0 in 2024, then sank by 39.94% to $450916.0 in 2025.
- Business Quant data shows VYNE's Treasury Shares at $450916.0 in Q4 2025, $750715.0 in Q4 2024, and $460979.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 5.14 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 450,916.00 |
| Dec 31, 2025 | 450,916.00 |
| Dec 31, 2024 | 750,715.00 |
| Dec 31, 2024 | 750,715.00 |
| Dec 31, 2023 | 460,979.00 |
| Dec 31, 2023 | 460,979.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2019 | 91,058.00 |
| Dec 31, 2019 | 91,058.00 |
| Dec 31, 2017 | 11.85 Mn |
| Dec 31, 2017 | 11.85 Mn |
| Dec 31, 2016 | 14.11 Mn |
| Dec 31, 2016 | 14.11 Mn |